Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers-Reference-Cited by-同舟云学术

Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers

Published:2024-08-23 Issue: Volume: Page:1-7
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Schinke Carolina¹^ORCID,Dhakal Binod²,Mazzoni Sandra³,Shenoy Samantha⁴,Scott Sara A.⁵,Richards Tiffany⁶,Le Hoa H.⁷,DeBrosse Amalia⁸,Okorozo Peter⁸,McDowell Rachel⁸,Patel Saurabh⁷,Bunn Jonathan⁷,Hawks Kelly⁷,Zhang Xinke⁷,Rodriguez Cesar⁹

Affiliation:

1. University of Arkansas for Medical Sciences, Little Rock, AR, USA

2. Medical College of Wisconsin, Milwaukee, WI, USA

3. Cleveland Clinic, Cleveland, OH, USA

4. University of California, San Francisco, CA, USA

5. Winship Cancer Institute, Emory University, Atlanta, GA, USA

6. MD Anderson Cancer Center, Houston, TX, USA

7. Johnson & Johnson Innovative Medicine, Horsham, PA, USA

8. Avalere Health, New York, NY, USA

9. Mount Sinai School of Medicine, New York, NY, USA

Funder

Johnson & Johnson Innovative Medicine

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2387183

Reference9 articles.

1. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

2. Rasche L, Schinke C, Touzeau C, et al. Long-term efficacy and safety results from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Poster presented at the 29th European Hematology Association (EHA) Congress; 13–16 June 2024; Madrid, Spain.

3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

4. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

5. TALVEY™ (talquetamab-tgvs) [package insert]. Horsham (PA): Janssen Biotech, Inc; 2023.